Bio-Rad Laboratories, Inc. (NYSE:BIO) shares reached a new 52-week high during trading on Friday after Wells Fargo & Co raised their price target on the stock from $430.00 to $440.00. Wells Fargo & Co currently has an overweight rating on the stock. Bio-Rad Laboratories traded as high as $396.84 and last traded at $389.00, with a volume of 9902 shares changing hands. The stock had previously closed at $379.34.

Separately, Citigroup assumed coverage on shares of Bio-Rad Laboratories in a research note on Monday, January 6th. They set a “buy” rating and a $450.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $400.83.

A number of hedge funds have recently modified their holdings of BIO. Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Bio-Rad Laboratories during the 4th quarter worth about $6,048,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Bio-Rad Laboratories during the 4th quarter worth about $481,000. Asset Management One Co. Ltd. increased its stake in shares of Bio-Rad Laboratories by 788.1% during the 4th quarter. Asset Management One Co. Ltd. now owns 10,657 shares of the medical research company’s stock worth $3,943,000 after purchasing an additional 9,457 shares during the last quarter. Public Sector Pension Investment Board increased its stake in shares of Bio-Rad Laboratories by 154.8% during the 4th quarter. Public Sector Pension Investment Board now owns 10,700 shares of the medical research company’s stock worth $3,959,000 after purchasing an additional 6,500 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its stake in shares of Bio-Rad Laboratories by 562.9% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 7,570 shares of the medical research company’s stock worth $2,801,000 after purchasing an additional 6,428 shares during the last quarter. Hedge funds and other institutional investors own 63.94% of the company’s stock.

The company has a market capitalization of $11.07 billion, a price-to-earnings ratio of 31.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.16. The firm’s 50 day moving average price is $372.68 and its two-hundred day moving average price is $351.31. The company has a current ratio of 4.72, a quick ratio of 3.36 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.44 by ($0.12). Bio-Rad Laboratories had a return on equity of 4.30% and a net margin of 16.14%. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 7.2 EPS for the current year.

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Read More: Different Types of Derivatives

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.